MounjaBoost attracts consumer attention in 2025 for its plant‑based metabolism and energy‑balance support, with insight into formulation, ingredient philosophy, user feedback, and safety guidance
Read More
Transition extending life of mine production underway
Gold equivalent production of 11,437 Gold Equivalent Ounces ("GEO") at AISC of $1,779/oz during Q2 2025
Adjusted EBITDA of $7.4 million for Q2 2025
Full year guidance of 55,000-60,000 GEO maintained: Production weighted to H2 as higher-grade underground mining and heap leach volumes increase
Repayment of ~US$18m debt and payables at the MDN operations year to date- ~US$10m in Q2 2025
20,000 meter resource expansion exploration program at MDN underway
Significant investment and progress at both the Lagoa Salgada and Mont Sorcier projects
Positive Metallurgical results at Lagoa Salgada to be incorporated into Optimized Feasibility Study to be delivered by year end
Management to host conference call on Monday, 25th of August, 11AM EDT
Leading Pharmaceutical Manufacturers, Contract Research Organizations, and Academic Medical Centers Collaborate on Global Research Project Using DistillerSR.
Read More
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs
Read More
